Catalyst Prescription drugs Appoints Tamar Thompson to its Board of Administrators

CORAL GABLES, Fla., Could 30, 2023 (GLOBE NEWSWIRE) — Catalyst Prescription drugs, Inc. (“Catalyst” or “Firm”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical firm targeted on in-licensing, creating, and commercializing novel medicines for sufferers residing with uncommon illnesses, in the present day introduced the appointment of Ms. Tamar Thompson to the Firm’s Board of Administrators (“Board”), efficient on Could 25, 2023.

“We’re extraordinarily happy to welcome Tamar to our Board as she brings a wealth of expertise to our workforce throughout a number of therapeutic classes, together with uncommon illnesses, coupled with in depth well being coverage and authorities affairs acumen,” stated Patrick J. McEnany, Chairman and CEO of Catalyst. “Ms. Thompson’s distinguished business experience and management ideally align with Catalyst’s long-term progress technique. We look ahead to her invaluable contributions as we proceed executing our growth initiatives to offer modern uncommon neuroscience illness medicines to extra sufferers looking for novel therapy choices.”

“I’m honored to hitch the Catalyst Board at such a pivotal time within the Firm’s historical past,” stated Ms. Thompson. “Catalyst has skilled a really profitable evolution over the previous few years and is effectively positioned to additional capitalize on its established capabilities with further novel property that complement its rising product portfolio. I look ahead to collaborating with the Board and the Catalyst’s management workforce because the Firm advances its strategic progress plans.”

Ms. Thompson has greater than twenty years of management expertise in well being care, well being coverage technique, authorities affairs, and market entry, with a various background throughout a number of healthcare sectors and therapeutic classes, together with uncommon illnesses, with a deal with creating strategic and tactical suggestions to make sure optimum reimbursement and market entry for uncommon illness merchandise. Ms. Thompson presently serves as Vice President, Head of World Company Affairs for Alexion Pharmaceutical, AstraZeneca Uncommon Ailments. Previous to becoming a member of Alexion, Ms. Thompson served as Government Director, State Authorities Affairs and Federal Coverage for Bristol-Myers Squibb Firm. Previous to becoming a member of Bristol Myers Squibb, she served as a strategic coverage advisor and advisor for varied governmental affairs companies based mostly in Washington, D.C.

Story continues

Ms. Thompson obtained a Grasp of Science in Well being Sciences with a focus in Public Well being from Trident College in Cypress, California, and presently serves on the Board of Administrators of Avidity Biosciences.

About Catalyst Prescription drugs
With distinctive affected person focus, Catalyst is dedicated to creating and commercializing modern first-in-class medicines that tackle uncommon neurological and epileptic illnesses. Catalyst’s flagship U.S. industrial product is FIRDAPSE^® (amifampridine) Tablets 10 mg, authorized for the therapy of Lambert-Eaton myasthenic syndrome (“LEMS”) for adults and for youngsters ages six to seventeen. In January 2023, Catalyst acquired the U.S. industrial rights to FYCOMPA^® (perampanel) CIII, a prescription drugs authorized in individuals with epilepsy aged 4 and older alone or with different medicines to deal with partial-onset seizures with or with out secondarily generalized seizures and with different medicines to deal with major generalized tonic-clonic seizures for individuals with epilepsy aged 12 and older. Additional, Canada’s nationwide healthcare regulatory company, Well being Canada, has authorized using FIRDAPSE for the therapy of grownup sufferers in Canada with LEMS.

For Full Prescribing and Security Info for FIRDAPSE^®please go to www.firdapse.com. For Full Prescribing Info, together with Boxed WARNING for FYCOMPA^®please go to www.fycompa.com. For extra details about Catalyst Prescription drugs, Inc., go to the Firm’s web site at www.catalystpharma.com.

Ahead-Wanting Statements
This press launch comprises forward-looking statements. Ahead-looking statements contain identified and unknown dangers and uncertainties, which can trigger Catalyst’s precise ends in future durations to vary materially from forecasted outcomes. Plenty of elements, together with these elements described in Catalyst’s Annual Report on Type 10-Okay for the fiscal 12 months 2022 and its different filings with the U.S. Securities and Alternate Fee (“SEC”), might adversely have an effect on Catalyst. Copies of Catalyst’s filings with the SEC can be found from the SEC, could also be discovered on Catalyst’s websiteor could also be obtained upon request from Catalyst. Catalyst doesn’t undertake any obligation to replace the data contained herein, which speaks solely as of this date.

Supply: Catalyst Prescription drugs, Inc.

CONTACT: Investor Relations Contact: Mary Coleman Catalyst Prescription drugs (305) 420-3200 [email protected] Media Contact: David Schull Russo Companions (858) 717-2310 [email protected]